Healthcare · Medical - Diagnostics & Research
Price
$113.02
Market Cap
$12.6B
Employees
11,000
Beta
1.11
Avg Volume
1,300,396
CEO
Prahlad R. Singh
Business Description
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Business History
Price Overview
Last updated: Jun 27, 2026 8:58am (just now)$113.02
-0.51 (-0.45%)
Day Range
$111.75 – $116.16
52-Week Range
$81.22 – $118.30
50-Day MA
$96.92
200-Day MA
$96.05
Volume
2,401,375.00
Analyst Price Targets
Low
$95.00
Consensus
$110.57
High
$124.00
(28 analysts)
Share Structure
Outstanding
111,560,000.00
Float
102,135,203.00
Free Float
91.6%
High free float
— 91.6% of shares trade freely, ~8.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
52.48
Stock Price: $113.02
EPS (Diluted): 2.08
EPS (Diluted): 2.08
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.52
Stock Price: $113.02
Total Equity: $7.25B
Shares: 113,214,000
Total Equity: $7.25B
Shares: 113,214,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
19.54
Market Cap: $12.61B
Total Debt: $3.37B
Cash: $919.87M
EBITDA: $662.72M
Total Debt: $3.37B
Cash: $919.87M
EBITDA: $662.72M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$13.6B
Market Cap: $12.61B
Total Debt: $3.37B
Cash: $919.87M
Total Debt: $3.37B
Cash: $919.87M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
53.1%
Gross Profit: $1.52B
Revenue: $2.86B
Revenue: $2.86B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
12.5%
Operating Income: $356.64M
Revenue: $2.86B
Revenue: $2.86B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
8.5%
Net Income: $241.68M
Revenue: $2.86B
Revenue: $2.86B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
3.3%
Net Income: $241.68M
Total Equity: $7.25B
Total Equity: $7.25B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
2.9%
Operating Income: $356.64M
Tax Rate: 9.6%
Equity: $7.25B
Total Debt: $3.37B
Cash: $919.87M
Tax Rate: 9.6%
Equity: $7.25B
Total Debt: $3.37B
Cash: $919.87M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.68
Current Assets: $2.24B
Current Liabilities: $1.33B
Current Liabilities: $1.33B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.46
Short-Term Debt: $588.83M
Long-Term Debt: $2.78B
Total Debt: $3.37B
Total Equity: $7.25B
Long-Term Debt: $2.78B
Total Debt: $3.37B
Total Equity: $7.25B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$25.23
Revenue: $2.86B
Shares: 113,214,000
Shares: 113,214,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$64.04
Total Equity: $7.25B
Shares: 113,214,000
Shares: 113,214,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$4.49
Operating CF: $581.78M
CapEx: -$73.52M
Shares: 113,214,000
CapEx: -$73.52M
Shares: 113,214,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.3%
Last Dividend: N/A
Stock Price: $113.02
Stock Price: $113.02
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $241.68M
Net Income: $241.68M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares RVTY against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| Cost of Revenue | $1.5B | $1.6B | $1.4B | $1.4B | $1.3B |
| Gross Profit | $2.3B | $1.8B | $1.3B | $1.3B | $1.5B |
| Operating Expenses | $941.9M | $979.6M | $922.7M | $912.1M | $1.2B |
| Operating Income | $1.3B | $781.1M | $399.5M | $410.5M | $356.6M |
| Net Income | $943.2M | $569.2M | -$118.4M | $295.8M | $241.7M |
| EBITDA | $1.6B | $1.2B | $713.6M | $840.3M | $662.7M |
| EPS | $8.12 | $4.51 | $-0.95 | $2.41 | $2.08 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $603.3M | $454.4M | $913.2M | $1.2B | $919.9M |
| Total Current Assets | $2.4B | $3.3B | $3.0B | $2.3B | $2.2B |
| Total Assets | $15.0B | $14.1B | $13.6B | $12.4B | $12.2B |
| Current Liabilities | $1.2B | $1.5B | $1.5B | $653.1M | $1.3B |
| Long-Term Debt | $5.0B | $3.9B | $3.2B | $3.2B | $2.8B |
| Total Liabilities | $7.9B | $6.7B | $5.7B | $4.7B | $4.9B |
| Total Equity | $7.1B | $7.4B | $7.9B | $7.7B | $7.3B |
| Retained Earnings | $4.4B | $5.0B | $5.6B | $5.8B | $6.1B |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.4B | $679.8M | $91.3M | $628.3M | $581.8M |
| Capital Expenditure | -$86.0M | -$85.6M | -$81.4M | -$86.6M | -$73.5M |
| Free Cash Flow | $1.3B | $594.2M | $9.9M | $541.7M | $508.3M |
| Acquisitions (net) | -$4.0B | $7.0M | -$1.9M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$73.1M | -$80.6M | -$388.9M | -$369.6M | -$820.8M |
| Net Change in Cash | $216.7M | -$148.6M | $443.6M | $250.1M | -$244.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:58am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$3.0B $3.0B – $3.0B
|
$3.2B $3.2B – $3.2B
|
$3.4B $3.3B – $3.4B
|
$3.5B $3.5B – $3.6B
|
| EBITDA |
$939.3M $933.0M – $948.8M
|
$997.4M $997.2M – $997.7M
|
$1.1B $1.1B – $1.1B
|
$1.1B $1.1B – $1.1B
|
| Net Income |
$662.8M $656.0M – $669.7M
|
$733.4M $721.1M – $745.6M
|
$783.2M $779.0M – $790.1M
|
$817.5M $813.2M – $824.7M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -13.5% | -16.9% | +0.2% | +3.7% |
| Gross Profit Growth | -22.8% | -24.9% | +0.0% | +14.6% |
| Operating Income Growth | -41.7% | -48.9% | +2.8% | -13.1% |
| Net Income Growth | -39.7% | -120.8% | +349.9% | -18.3% |
| EBITDA Growth | -26.9% | -39.7% | +17.8% | -21.1% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Gonzales Anita | F-InKind | 33.00 | $99.66 | $3,289 |
| 2026-05-07 | MICHAS ALEXIS P | A-Award | 1,467.00 | $0.00 | $0 |
| 2026-05-07 | MICHAS ALEXIS P | A-Award | 1,217.00 | $0.00 | $0 |
| 2026-05-07 | Vandebroek Sophie V. | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Vandebroek Sophie V. | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Klobuchar Michael A | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Klobuchar Michael A | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Witney Frank | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Witney Frank | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Chapin Samuel R. | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Chapin Samuel R. | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Vounatsos Michel | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Vounatsos Michel | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | McMurry-Heath Michelle | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | McMurry-Heath Michelle | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Barrett Peter | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Barrett Peter | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-05-07 | Witz Pascale | A-Award | 1,265.00 | $0.00 | $0 |
| 2026-05-07 | Witz Pascale | A-Award | 1,015.00 | $0.00 | $0 |
| 2026-04-20 | Gonzales Anita | S-Sale | 80.00 | $92.80 | $7,424 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:51pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-17 | $0.07 | 2026-04-30 | 2026-07-17 | 2026-08-07 |
| 2026-04-17 | $0.07 | 2026-01-26 | 2026-04-17 | 2026-05-08 |
| 2026-01-16 | $0.07 | 2025-10-23 | 2026-01-16 | 2026-02-06 |
| 2025-10-17 | $0.07 | 2025-07-24 | 2025-10-17 | 2025-11-07 |
| 2025-07-18 | $0.07 | 2025-04-24 | 2025-07-18 | 2025-08-08 |
| 2025-04-17 | $0.07 | 2025-01-23 | 2025-04-18 | 2025-05-09 |
| 2025-01-17 | $0.07 | 2024-10-24 | 2025-01-17 | 2025-02-07 |
| 2024-10-18 | $0.07 | 2024-07-25 | 2024-10-18 | 2024-11-08 |
| 2024-07-19 | $0.07 | 2024-04-25 | 2024-07-19 | 2024-08-09 |
| 2024-04-18 | $0.07 | 2024-01-25 | 2024-04-19 | 2024-05-10 |
| 2024-01-18 | $0.07 | 2023-10-26 | 2024-01-19 | 2024-02-09 |
| 2023-10-19 | $0.07 | 2023-07-21 | 2023-10-20 | 2023-11-10 |
| 2023-07-20 | $0.07 | 2023-04-25 | 2023-07-21 | 2023-08-11 |
| 2023-04-20 | $0.07 | 2023-04-21 | 2023-05-12 | |
| 2023-01-19 | $0.07 | 2023-01-20 | 2023-02-10 | |
| 2022-10-20 | $0.07 | 2022-10-21 | 2022-11-11 | |
| 2022-07-21 | $0.07 | 2022-07-22 | 2022-08-12 | |
| 2022-04-21 | $0.07 | 2022-04-22 | 2022-05-13 | |
| 2022-01-20 | $0.07 | 2022-01-21 | 2022-02-11 | |
| 2021-10-21 | $0.07 | 2021-10-22 | 2021-11-12 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for RVTY — it's generated by the pipeline (
market-narrative step).
No community reviews yet for RVTY.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30